From: Serum uri acid: neuroprotection in thrombolysis. The Bergen NORSTROKE study
rt-PA | Non rt-PA | Late | p | |
---|---|---|---|---|
Sample size, n | 186 | 261 | 689 | |
Time to blood sample, h (IR) | 1.5 (1.0-2.4) | 1.9 (1.4-2.7) | 18.7 (9.3-31.1) | |
Age, years (SD) | 69.3 (± 14.2) | 70.9 (± 14.1) | 71.4 (± 14.6) | 0.21 |
Male Sex, n (%) | 118 (63.4) | 149 (57.1) | 385 (± 55.9) | 0.17 |
Median NIHSS day 0* (IR) | 9.5 (4-17) | 3 (1-5) | 3 (1-7) | 0.0001 |
NIHSS day 0, n (%) | 0.0001 | |||
< 8 | 76 (40.9) | 216 (82.7) | 524 (76.1) | |
8-14 | 42 (22.6) | 13 (7.3) | 78 (11.3) | |
> 14 | 68 (36.5) | 26 (10.0) | 87 (12.6) | |
SUA levels, μmol/L, n (%) | 0.2 | |||
< 305 | 56 (29.5) | 93 (34.7) | 257 (33.5) | |
305-399 | 63 (33.2) | 100 (37.3) | 249 (32.5) | |
≥ 400 | 71 (37.4) | 75 (28.0) | 260 (34.0) | |
Creatinine, μmol/L, n (%) | 0.4 | |||
< 120 | 169 (91.0) | 247 (92.1) | 687 (89.7) | |
≥ 120 | 17 (9.0) | 21 (7.9) | 79 (10.3) | |
SBP day 0, mmHg (SD) | 162.0 (± 25.9) | 168.5 (± 29.3) | 167.5 (± 33.6) | 0.05 |
Previous diseases, n (%) | ||||
Hypertension | 92 (49.5) | 133 (50.0) | 415 (54.6) | 0.3 |
Diabetes | 23 (12.4) | 33 (12.6) | 119 (15.8) | 0.3 |
Stroke | 21 (11.0) | 58 (21.7) | 145 (19.1) | 0.01 |
TIA | 18 (9.4) | 28 (10.5) | 71 (9.3) | 0.8 |
Median mRS day 7 (IR) | 2 (1-4) | 2 (1-3) | 2 (1-4) | 0.01 |